Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRIM1 divergent transcript (CRIM1-DT)
- Target
- CRIM1-DT
- Molecular classification
- Long noncoding RNA (lncRNA), Noncoding RNA
01
Overview
CRIM1 divergent transcript (CRIM1-DT) is a long noncoding RNA (lncRNA) that is divergently transcribed from the CRIM1 gene region. Divergent lncRNAs are a common feature in mammalian gene regulation, often arising from bidirectional promoter activity near protein-coding genes and may be involved in regulation of gene expression, although their individual functions are frequently uncharacterized[2][4]. The specific biological role, therapeutic relevance, and disease implications of CRIM1-DT (RP11-490M8.1) are not established in the literature. It should not be confused with the CRIM1 protein or with circCRIM1, a circular RNA from the same locus implicated in cancer metastasis and drug resistance[1][3]. The CRIM1 divergent transcript is not a validated drug target, enzyme, transporter, or receptor and has no known clinical or pharmacological significance.
- Other names
- RP11-490M8.1CRIM1-DT
02
Mechanism of action
None known
03
Biological functions
Other (The specific function of CRIM1-DT is unknown; more generally, divergent lncRNAs may participate in gene expression regulation, chromatin remodeling, and cis/trans acting effects on neighboring protein-coding genes[2][4].)
04
Disease associations
Other (No direct disease association or validated pathological role established for CRIM1-DT itself. Distinct circular RNA from the CRIM1 locus, "circCRIM1," is involved in nasopharyngeal carcinoma, but this is not equivalent to the CRIM1 divergent transcript/RP11-490M8.1[1].)
Beyond the preview
Go deeper on CRIM1 divergent transcript (CRIM1-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRIM1 divergent transcript (CRIM1-DT).